Clinical Data (CLDA) announces that its major depressive disorder treatment Viibryd received...


Clinical Data (CLDA) announces that its major depressive disorder treatment Viibryd received approval from the FDA. The biotech company says the drug should be available in U.S. pharmacies in Q2. CLDA +67.3% premarket. (PR)

From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs